Pliant is currently conducting clinical research studies in IPF and PSC. INTEGRIS-IPF and INTEGRIS-PSC clinical research studies are actively enrolling eligible participants.
If you are interested in learning more about these clinical trials, email us at email@example.com
IPF is a chronic and progressive fibrotic disease in which lung tissue becomes thickened, stiff and scarred, leading to increased difficulty in breathing and decreased quality of life. As lung fibrosis progresses, it becomes increasingly difficult for the lungs to transfer oxygen into the bloodstream— ultimately preventing vital organs from receiving the oxygen necessary to function properly. IPF currently affects approximately 140,000 people in the U.S.
Primary Sclerosing Cholangitis (PSC) is a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. With PSC, the bile ducts become inflamed, making it harder for the bile to travel through. As a result, the bile builds up inside the liver. Over time this could lead to increased scarring of the liver and potentially liver failure, for which a liver transplant may be needed. Currently, there is no approved treatment for PSC. PSC affects approximately 30,000 people in the U.S.